MARKET

ACET

ACET

Adicet Bio, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.60
+0.32
+4.40%
After Hours: 7.60 0 0.00% 16:00 09/24 EDT
OPEN
7.32
PREV CLOSE
7.28
HIGH
7.89
LOW
7.25
VOLUME
170.59K
TURNOVER
--
52 WEEK HIGH
17.80
52 WEEK LOW
6.25
MARKET CAP
242.00M
P/E (TTM)
-1.7080
1D
5D
1M
3M
1Y
5Y
Adicet Bio Collaborates with Twist Bioscience to Accelerate Discovery of Gamma Delta T Cell Cancer Therapeutics
MENLO PARK, Calif., and BOSTON, MA, and SOUTH SAN FRANCISCO, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer an...
GlobeNewswire · 09/13 12:00
Adicet Bio to Participate in Upcoming Investor Conferences
MENLO PARK, Calif. and BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that company manage...
GlobeNewswire · 09/02 20:53
ASND, GDS, ADSK and CDZI among after hours movers
Gainers: ASND +22.8%. GDS +7.0%. CD +5.6%. ULTA +5.4%. VRAY +4.7%. Losers: ADSK -6.8%. CDZI -5.3%. GNLN -4.7%. ACET -4.6%. AVNW -4.4%.
Seekingalpha · 08/25 21:38
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17)
Benzinga · 08/18 11:37
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11)
Benzinga · 08/12 12:09
Adicet Bio, Inc. (ACET) Reports Q2 Loss, Tops Revenue Estimates
Zacks.com · 08/12 09:10
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9)
Benzinga · 08/10 11:55
Johnson & Johnson Innovation - JJDC, Inc. ...
GuruFocus News · 08/03 18:38
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ACET. Analyze the recent business situations of Adicet Bio, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ACET stock price target is 28.29 with a high estimate of 34.00 and a low estimate of 22.00.
EPS
Institutional Holdings
Institutions: 111
Institutional Holdings: 34.07M
% Owned: 107.00%
Shares Outstanding: 31.84M
TypeInstitutionsShares
Increased
18
2.02M
New
20
503.47K
Decreased
15
1.43M
Sold Out
8
267.52K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.11%
Pharmaceuticals & Medical Research
-1.01%
Key Executives
President/Chief Executive Officer/Secretary/Director
Chen Schor
Chief Financial Officer
Nick Harvey
Chief Human Resource Officer/Senior Vice President
Carrie Krehlik
Senior Vice President
Francesco Galimi
Chief Technology Officer
Don Healey
Independent Director
Jeffrey Chodakewitz
Independent Director
Steve Dubin
Independent Director
Carl Gordon
Independent Director
Aya Jakobovits
Independent Director
Bastiano Sanna
Independent Director
Andrew Sinclair
No Data
About ACET
Adicet Bio Inc., formerly resTORbio, Inc., is a biotechnology company. The Company is focused on developing allogeneic gamma delta T cell therapies for cancer and other diseases. It is developing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enable selective tumor targeting, facilitate innate and adaptive anti-tumor immune response and improve persistence for durable activity in patients. Its pipeline includes ADI-001, ADI-002 and ADI-00x. ADI-001 is a gamma delta chimeric antigen receptor (CAR)-modified T cell therapy targeting CD20. ADI-002 is a gamma delta T cell containing a CAR that is specific for glypican 3 protein (GPC3). The Company is focused on developing ADI-00x for solid tumors and solid tumor and hematological indications.

Webull offers kinds of Adicet Bio Inc stock information, including NASDAQ:ACET real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACET stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACET stock methods without spending real money on the virtual paper trading platform.